Here we report a fifth case of this metabolic disease. On the basis of biochemical investigations we compare it with the four observations previously described in the literature and attempt to elucidate the metabolic lesion.
Urinary excretion of glyceric acid is particularly rare and is found in only two metabolic disorders: D-glyceric and L-glyceric acidurias. The two can be distinguished according to clinical picture and urinary organic acid profile. In D-glyceric aciduria, only glyceric acid appears as the pathological metabolite, whereas in L-glyceric aciduria (primary hyperoxaluria type 2), increased amounts of glyceric acid are associated with another abnormality such as increased oxalic acid, which causes clinical symptoms of recurrent nephrolithiasis (1) (2) (3) . This paper reports a new case of D-glyceric acidemia/ aciduria, studied essentially by gas chromatography and mass spectrometry (GC/MS). (4) (5) (6) (7) (8) .
Here we report a fifth case of this metabolic disease. On the basis of biochemical investigations we compare it with the four observations previously described in the literature and attempt to elucidate the metabolic lesion.
Case Report
Patient C. E., a nine-month-old girl, is the first child of consanguineous Turkish parents. During her admission ill the pediatric clinic, she presented with delayed psychomotor development, axial hypotonia, and spastic tetraparesia. Results of routine biochemical investigations were normal; in particular, no metabolic acidosis was detected. Study of amino acids in serum and urine showed no notable abnormality.
However, during screening of urinary organic acids by GC/MS, large amounts of an unusual compound, glyceric acid, were found repeatedly. The patient was on a normal diet and no treatment was required. Organic acid profiles showed no artefact attributable to drugs or dietary constituents.
Materials and Methods

Samples.
We collected 24-h urine specimens in four 6-h portions, without any additive. Plasma (obtained by use of heparinized tubes), cerebrospinal fluid, and urine specimens were stored at -20 #{176}C until extraction.
Instrumentation. We used a gas chromatograph (Model 8500; Perkin-Elmer, Bucks., U.K.) equipped with flame ionization detector and connected with a Perkin-Elmer GP 100 graphic printer.
A A preliminary deproteinization with nine volumes of ethanol was necessary for plasma samples. We analyzed D-glyceraldehyde and -hydroxypyruvic acid as TMSmethoxime derivatives (9).
Gas chromatography procedure. The analytical procedure was as follows: carrier gas helium at a pressure of 83 kPa; injector temperature 300#{176}C; detector temperature 300#{176}C; initial oven temperature 65#{176}C for 6 miii, then
programmed to 250#{176}C at a rate of 4 #{176}C/min, with the final temperature maintained for 5 mm. Mass spectra were recorded at an ionization potential of 70 eV. Identification of all TMS derivatives, according to their retention times and methylene unit values, was confirmed by GCIMS. Quantitative analysis of glyceric acid. We determined concentrations of this metabolite by two different methods: GC, with reference to calibration curves established with D-glyceric acid standards solubilized in the same biological fluids as the analyzed samples, and a fully automated procedure on a centrifugal analyzer (Cobas Bio, Roche S. A., Neuilly, France), based on use of D-glycerate dehydrogenase, which is specific for the D-form of glyceric acid (10). Urinary glyceric acid concentrations were expressed in ratios with creatiine excretion, creatinine being usu-' ally considered as the best reference in quantitative studies of organic acidurias, particularly in the newborn (11). Characterization of glyceric acid stereoisomer form. Several methods can be used for the determination of the enantiomer form of glyceric acid: GC analysis of O-acetylated menthyl esters (12), polarimetry (10, 13), and enzymatic stereospecificity of D-glycerate dehydrogenase (10, 13). We performed these two last methods in our laboratory. We isolated glyceric acid from the patient's urine by anion-exchange chromatography on diethylaminoethylSephadex A-25,according to Chalmers and Watts (14) . We studied optical rotatory dispersion between 296 and 365 nm by using a Perkin-Elmer 141 M.C. spectropolarimeter. The configuration was also confirmed by the enzymatic specificity of D-glycerate dehydrogenase-both by measuring variation of optical rotatory dispersion and by detecting at 340 nm the NADH generated.
Quantitative analysis of other metabolites. We determined oxalic acid and glycolic acid in urine by CC. In plasma and urine, we evaluated glycerol by a classical enzymatic procedure, using a test combination from Boehringer, Mannheim, F.R.G. All the metabolites in the 2-phospho-D-glycerate pathway were simultaneously studied with reagents from the 2,3-diphosphoglycerate test combination (Boehringer).
Results
Urinary organic acid screening and glyceric acid characterization. All the chromatograms showed a large peak (methylene unit value, 13.49) that was identified as glyceric acid by mass spectrometry.
No other abnormal peaks were detected, but to rule out the possibility of an L-glyceric aciduria, we checked for oxalic acid in a few urine specimens. Oxalic On the other hand, during the fructose loading test, we observed the following: in plasma, fructose increased rapidly, by 233 moJ/L after 15 mm, then decreased while glyceric acid was increasing by 120 1tmoIJL (Figure 1) . In urine, glyceric acid increased from 64 to 83.7 pmollg creatinine.
Consequently, in our patient, both fructose and 1-serine loading tests led to an increase of glyceric acid, but the most impressive response was during the L-serine test. D-Glyceric acid remained undetectable in urine specimens from the patient's parents before and after their fructose loading test. We could not test them with L-serine loading.
Dietary restriction tests. We placed the patient on a fructose-free diet and a protein-restriction diet for several days. We saw no decrease of D-glyceric acid excretion after those restriction tests.
Study of other intermediate metabolites.
All the metabolites involved in the different metabolic pathways of glyceric acid were investigated during the loading tests (see Figure 2 ). D-Glyceraldehyde and (3-hydroxypyruvic acid remained undetectable even in fresh urinary specimens. We obtained the same results for plasma samples.
Free glycerol concentrations in plasma and urine showed no abnormality: from 5.6 to 14.6 mg/L in plasma (normal range: 5-17 mg/L) and from 0 to 12 mg/L in urine without any variation during loading tests. Determination of all the metabolites of the 2-phospho-D-glycerate metabolic pathway (2-phospho-D-glycerate, 3-phospho-D-glycerate, 3 phospho-D-glyceraldehyde, and dihydroxyacetone phosphate) revealed no increase in any of them in any sample examined.
DIscussion
From the results given here, it becomes clear that our patient suffers from D-glyceric acidemia. Table 1 In our case, it is evident that both L-serine and fructose can bethought to be precursors of D-glycerate biosynthesis. Our observation differs from the other cases because our patient is the only one who reacted to the two loading tests.
Three metabolic pathways are involved in human Dglycerate metabolism (see Figure 2 ). In our patient, the loading tests give us the following information. D-Glycerate dehydrogenase integrity was proved by the metabolic effects of L-serine: increasing D-glycerate concentrations and lack of accumulation of hydroxypyruvate and L-glycerate during the test. Aldehyde dehydrogenase deficiency is unlikely because our patient also reacted to the fructose loading test with increases in D-glycerate. During this test, D-glycerate excretion was less impressive than in the patient of Duran et al. Therefore, we conclude that, unlike their patient, ours does not seem to be defective in triokinase, the major enzyme involved in D-glyceraldehyde catabolism (19, 20) .
Thus, as judged by the results of the two loading tests, the primary enzymatic defect must be located on a metabolic pathway shared by fructose and L-serine. Consequently, only a deficiency of D-glycerate kinase (EC 2.7.1.3 1) would explain such a D-glycerate accumulation. Nevertheless, considering the low activity of D-glycerate kinase in human liver (21) , a metabolic lesion located on one of the major L-serine catabolic pathways cannot be totally ruled out. In this case, D-glycerate biosynthesis from 1-serine would be increased and so capacity to metabolize D-glycerate by D-glycerate kinase would be surpassed.
Among the four observations of D-glyceric acidemia previously described in the literature, no enzymatic lesion could be definitely elucidated. However, according to loading test results, various hypotheses were proposed concerning the possible enzymatic defect (see Table 1 ).
In conclusion, we suggest that D-glycerate excretion is a feature shared by several different metabolic disorders. It can be related to single or multiple enzymatic defects in either the fructose or the L-serine metabolic pathways, or both.
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